18[F]FDG-PET/CT is a Useful Molecular Marker in Evaluating Tumour Aggressiveness: A Revised Understanding of an In-Vivo FDG-PET Imaging that Alludes the Alteration of Cancer Biology

Molecular imaging employing 18[F]FDG-PET/CT enables in-vivo visualization, characterisation and measurement of biological process in tumour at the molecular and cellular level. In oncology, this approach can be directly applied as translational biomarkers of disease progression. In this article, the improved roles of FDG as an in-vivo glycolytic marker which reflect biological changes across in-vitro cellular environment are discussed. New understanding in how altered metabolism via glycolytic downstream drivers of malignant transformation as reviewed below offers unique promise as to monitor tumour aggressiveness and hence optimize the therapeutic management.

[1]  Sigrid Stroobants,et al.  The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .

[2]  H. Abdel-Nabi,et al.  Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules. , 2008, Journal of hematology & oncology.

[3]  J. Talbot,et al.  Prospective Comparison of FDG and FET PET/CT in Patients with Head and Neck Squamous Cell Carcinoma , 2008, Molecular Imaging and Biology.

[4]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[5]  J M Hoffman,et al.  Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  S. Shiono,et al.  Positron Emission Tomography/Computed Tomography and Lymphovascular Invasion Predict Recurrence in Stage I Lung Cancers , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  V Kalff,et al.  The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  W. Brenner,et al.  Risk assessment in liposarcoma patients based on FDG PET imaging , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[10]  Philip Smith,et al.  Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. , 2009, The Journal of thoracic and cardiovascular surgery.

[11]  A. Alavi,et al.  Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Seong-Jang Kim,et al.  Open Access RESEARCH , 2010 .

[13]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Andrew Homb,et al.  18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.

[15]  S. Larson,et al.  18F-FDG PET Scanning Correlates with Tissue Markers of Poor Prognosis and Predicts Mortality for Patients After Liver Resection for Colorectal Metastases , 2007, Journal of Nuclear Medicine.

[16]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[17]  M. Younes,et al.  Human erythrocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  Lijuan Yu,et al.  Correlation of 18F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer , 2009, Nuclear medicine communications.

[19]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[20]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Dewhirst,et al.  Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.

[22]  C. Perry,et al.  Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. , 2003, Drugs.

[23]  C. Van de Wiele,et al.  FDG uptake, a surrogate of tumour hypoxia? , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  J. Choi,et al.  18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  H. Jun,et al.  Recent advances in insulin gene therapy for type 1 diabetes. , 2002, Trends in molecular medicine.

[26]  Philippe Lambin,et al.  The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. , 2007, European journal of cancer.

[27]  C. Graham,et al.  Nitric oxide‐mediated regulation of hypoxia‐induced B16F10 melanoma metastasis , 2004, International journal of cancer.

[28]  Jeffrey S. Morris,et al.  Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma , 2008, Clinical Cancer Research.

[29]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Hong,et al.  Prognostic Value of Primary Tumor Uptake on F-18 FDG PET/CT in Patients with Invasive Ductal Breast Cancer , 2011, Nuclear medicine and molecular imaging.

[31]  Sang Moo Lim,et al.  Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. , 2009, Nuclear medicine and biology.

[32]  Y. Ishigaki,et al.  VEGF-A and its isoform VEGF121 mRNA expression measured by quantitative real-time RT-PCR: correlation with F-18 FDG uptake and aggressiveness of lung adenocarcinoma: preliminary study , 2011, Annals of nuclear medicine.

[33]  Dwight E Heron,et al.  PET-CT in Radiation Oncology: The Impact on Diagnosis, Treatment Planning, and Assessment of Treatment Response , 2008, American journal of clinical oncology.

[34]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[35]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[36]  Jane Bayani,et al.  Genomic mechanisms and measurement of structural and numerical instability in cancer cells. , 2007, Seminars in cancer biology.

[37]  Adrian L Harris,et al.  Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. , 2006, Cancer research.

[38]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[39]  A. Folpe,et al.  (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.